Holen Sie sich die Stockscreener-App
7.43
3.26%
-0.25
Handel nachbörslich:
7.43
Schlusskurs vom Vortag:
$7.68
Offen:
$7.925
24-Stunden-Volumen:
1.19M
Relative Volume:
0.88
Marktkapitalisierung:
$480.61M
Einnahmen:
$202.09M
Nettoeinkommen (Verlust:
$-61.69M
KGV:
-6.8796
EPS:
-1.08
Netto-Cashflow:
$-35.64M
1W Leistung:
+11.06%
1M Leistung:
-22.04%
6M Leistung:
-46.78%
1J Leistung:
-53.15%
1-Tages-Spanne:
$7.34
$7.95
1-Wochen-Bereich:
$6.88
$7.95
52-Wochen-Spanne:
$5.71
$17.82
Evolus Inc Stock (EOLS) Company Profile
Firmenname
Evolus Inc
Sektor
Telefon
(949) 284-4555
Adresse
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Vergleichen Sie EOLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
7.43 | 432.75M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
155.10 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.07 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.675 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.12 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
305.38 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Herabstufung | Needham | Buy → Hold |
| 2025-04-17 | Eingeleitet | BTIG Research | Buy |
| 2024-01-29 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-06-23 | Eingeleitet | Needham | Buy |
| 2022-05-12 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2021-05-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-04-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-24 | Herabstufung | Truist | Buy → Hold |
| 2020-07-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-02-06 | Fortgesetzt | Mizuho | Buy |
| 2019-11-26 | Eingeleitet | SVB Leerink | Outperform |
| 2019-09-05 | Fortgesetzt | Mizuho | Buy |
| 2019-06-28 | Eingeleitet | Wells Fargo | Market Perform |
| 2019-06-11 | Eingeleitet | Barclays | Underweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-01-29 | Eingeleitet | Stifel | Buy |
Alle ansehen
Evolus Inc Aktie (EOLS) Neueste Nachrichten
Brady Stewart Bought 59% More Shares In Evolus - simplywall.st
Evolus Submits Evolysse Sculpt for FDA Approval, Expanding HA Dermal Filler Portfolio - Dermatology Times
Evolus submits Evolysse premarket approval application to FDA - TipRanks
Evolus submits final FDA application for mid-face volume filler - Investing.com
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse?? Sculpt Injectable Hyaluronic Acid Gel Product - MarketScreener
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product - Business Wire
Evolus plunges after Q2 miss, guidance cut; Needham downgrades - MSN
Director’s Bold Move: Major Stock Purchase Signals Confidence in Evolus - TipRanks
Evolus Sees Aesthetic Market Slowing After Q2 Miss - Orange County Business Journal
Is Evolus Inc. stock technically oversold2025 Trading Volume Trends & Low Drawdown Momentum Trade Ideas - thegnnews.com
Is Evolus Inc. Forming a Consolidation BaseJuly 2025 Recap & Trade Opportunity Analysis - metal.it
Live Scanner Shows Breakout on Evolus Inc.Jobs Report & Verified High Yield Trade Plans - 선데이타임즈
Evolus announces commercial launch of Evolysse - MSN
Midday Stock Roundup: ICU Medical Soars, Willdan Group Down - Orange County Business Journal
Is This the Dip to Buy in Evolus Inc.July 2025 Pullbacks & Capital Protection Trade Alerts - metal.it
Resistance Break Could Fuel Evolus Inc. Rally2025 Risk Factors & High Accuracy Swing Entry Alerts - classian.co.kr
Evolus Q2 2025: Unpacking Contradictions in Toxin Demand, Evolysse Launch, and Consumer Sentiment - AInvest
Evolus, Inc. shares rise 11.53% intraday after reporting inducement grants to new employees. - AInvest
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
How liquid is Evolus Inc. stockNext Day Profit Stock Signals - newsyoung.net
Analysts Just Slashed Their Evolus, Inc. (NASDAQ:EOLS) EPS Numbers - simplywall.st
Evolus (EOLS): Navigating Earnings Revisions and Long-Term Potential in the Aesthetic Medicine Sector - AInvest
Evolus, Inc. Sees Significant Downgrades to Consensus EPS Estimates - AInvest
The Consensus EPS Estimates For Evolus, Inc. (NASDAQ:EOLS) Just Fell Dramatically - Yahoo Finance
The recent earnings and revenue miss by Evolus EOLS -2.80% (EOLS) has sent shockwaves through the aesthetic medicine sector, with sharp downward revisions in analyst expectations raising questions about the company's long-term viability. Q2 2025 res - AInvest
When Will Evolus, Inc. (NASDAQ:EOLS) Turn A Profit? - 富途牛牛
Evolus, Inc. Faces Financial Uncertainty Due to Consumer Spending Risks and Economic Volatility - AInvest
Evolus Receives Buy Rating from Leerink Partners - AInvest
Evolus, Inc. Advances Safety Study of NUCEIVA for Glabellar Lines - TipRanks
A Quick Look at Today's Ratings for Evolus(EOLS.US), With a Forecast Between $18 to $20 - 富途牛牛
Evolus, Inc. (NASDAQ:EOLS) Q2 2025 Earnings Call Transcript - Insider Monkey
Evolus, Inc. Faces Financial Instability Amid Economic Uncertainty and Consumer Spending Risks - TipRanks
Evolus Q2 Earnings: Mixed Sentiments and Strategic Goals for Growth - AInvest
Evolus Maintains Buy Rating Amid Market Challenges Despite Reset in 2025 Revenue Guidance - AInvest
Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates - MSN
Evolus, Inc. Earnings Call: Mixed Sentiments and Strategic Goals - TipRanks
Evolus Appoints New Principal Financial Officer - MSN
Evolus 2025 Q2 Earnings Misses Targets, Net Loss Widens by 51% - AInvest
Evolus stock down on Q2 miss; Needham downgrades (EOLS:NASDAQ) - Seeking Alpha
Evolus, Inc. shares fall 30.53% intraday after disappointing Q2 earnings and lowered 2025 sales target. - AInvest
Evolus Sees Steady Gains And Eyes Profit Next Year - Finimize
Evolus Reports Q2 Revenue of $69.4mln, Misses Estimates by 15.4%, Lowers Full-Year Guidance - AInvest
Evolus stock price target lowered to $20 by H.C. Wainwright on market headwinds - Investing.com Canada
Evolus price target lowered to $18 from $21 at BTIG - TipRanks
Evolus: HC Wainwright Maintains Buy, PT Down to $20 from $27 - AInvest
Evolus stock price target lowered to $18 at BTIG on Q2 revenue miss By Investing.com - Investing.com South Africa
Evolus stock price target lowered to $18 at BTIG on Q2 revenue miss - Investing.com India
Evolus Stock Plunges 25.14% on Disappointing Earnings - AInvest
Evolus Q2 2025 slides: Filler launch drives market expansion despite earnings miss - Investing.com Nigeria
Evolus, Inc. Reports Q2 2025 Financial Results - TipRanks
Evolus outlines $700M 2028 revenue target and cost realignment amid market softness - MSN
Finanzdaten der Evolus Inc-Aktie (EOLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Evolus Inc-Aktie (EOLS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MOATAZEDI DAVID | See Remarks |
Jun 13 '25 |
Sale |
10.05 |
111,323 |
1,119,141 |
381,509 |
| MOATAZEDI DAVID | See Remarks |
Jun 16 '25 |
Sale |
9.89 |
16,582 |
164,054 |
364,927 |
2.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):